Skip to content

A Study of SPY002-072 in Healthy Volunteers

Healthy

This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 to 60

Participation Criteria

Inclusion Criteria:

* Healthy men and women
* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits

Exclusion Criteria:

* Participation in more than one cohort
* Evidence of clinically significant abnormality or disease
* Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
* History of severe allergic reactions or hypersensitivity
* Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing

Study Location

Spyre Site 1
Spyre Site 1
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Claudia Romero de los Reyes

[email protected]
450-973-3155 Ext. 113282
Study Sponsored By
Spyre Therapeutics, Inc.
Participants Required
More Information
Study ID: NCT06622070